3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
2
Recruiting
2
Completed
2
Active not recruiting
2
Withdrawn
1
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
27
Lung Neoplasms
7
NSCLC
2
Meningeal Carcinomatosis
2
Bronchial Neoplasms
2
Brain Neoplasms
2
Non-Small Cell Lung Cancer With EGFR T790M Mutation
1
Neurocognitive
1
Advanced Non-small Cell Lung Cancer
1
Interventions
Gefitinib
5
icotinib
4
Pemetrexed
4
Docetaxel
4
camrelizumab
3
apatinib
3
anlotinib
3
aflutinib
3
Erlotinib Hydrochloride
3
osimertinib
2
dacomitinib
2
Thalidomide
2
Radiosurgery
2
Drug Therapy
2
Carboplatin
2
Afatinib
2
trilaciclib
1
spartalizumab
1
pembrolizumab
1
nimotuzumab
1
famitinib
1
envafolimab
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
S 1 (combination)
1
Radiofrequency Ablation
1
Microphysiological Systems
1
Immune Checkpoint Inhibitors
1
Cisplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
NSCLC
×
osimertinib
×
Clear all
NCT04811001
2023-02-21
CAPLAND
Fondazione Ricerca Traslazionale
Phase 2
Unknown
170 enrolled
NCT04575415
2020-10-20
BELLA
Guangdong Association of Clinical Trials
Unknown
272 enrolled